appScorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Glenmark Pharmaceuticals Ltd
GLENMARK
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Company Profile
Glenmark Pharmaceuticals Limited is a global pharmaceutical company engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).
Brands
Investor PresentationView older
View Older PresentationsBrands
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Zydus Lifesciences Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
Low Pledged Promoter HoldingLower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Stock that will see action today: 18 July 2024
1 week ago•The Hindu Businessline
Glenmark Pharma receives USFDA approval for seizure treatment drug
1 week ago•Business Standard
USFDA approves Glenmark Pharma’s seizure treatment drug
1 week ago•Economic Times
Recent EventsAll events
Press Release
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 17, 2024, titled "Glenmark Pharmaceuticals receives ANDA approval for Topiramate Capsules USP, 15 mg and 25 mg". | Download
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 17, 2024, titled "Glenmark Pharmaceuticals receives ANDA approval for Topiramate Capsules USP, 15 mg and 25 mg". | Download
Press Release
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 12, 2024, titled "Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC)". | Download
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated Jun 12, 2024, titled "Glenmark receives ANDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC)". | Download
Cash Dividend
Final • Div/Share: ₹ 2.5
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant